NEW YORK – Candel Therapeutics on Thursday priced a public offering of common stock and pre-funded warrants that is expected to bring in $80 million in gross proceeds. The Needham, Massachusetts-based ...

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

NEW YORK – Leapfrog Bio on Wednesday said it will move on to a Phase II trial of its bromodomain and extra-terminal domain (BET) protein inhibitor LFB-190 in lung, colon, and bladder cancer after ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

SpliceBio aims to begin a study testing its protein splicing gene therapy in the first half of 2025, now that the FDA has cleared its IND.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...